Investors give Orum Therapeutics’ unique take on protein degraders another nudge toward the clinic

While protein degraders have seen an influx of cash in recent years, the small molecule drugs tend to run into toxicity problems, due to their difficulty differentiating healthy cells from cancerous ones. Orum Therapeutics thinks it has a solution — and the idea has investors reaching a little deeper into...

Click to view original post